Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2014

Manji R, Bythrow M, Branda JA, Burnham C-, Ferraro MJ, Garner OB, et al. Multi-center evaluation of the VITEK® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli. Eur J Clin Microbiol Infect Dis. 2014;33(3):337-46.

Scaglia N, Tyekucheva S, Zadra G, Photopoulos C, Loda M. De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. Cell Cycle. 2014;13(5):859-68.

Osakwe NC, Tong J, Rodgers WH, Kansler AL, Lee PC, Paul S. A rare case of fetal adenocarcinoma of the lung. Ann Thorac Surg. 2014;98(6):2217-8.

Hernandez ED, Lee SJ, Kim JY, Duran A, Linares JF, Yajima T, et al. A macrophage NBR1-MEKK3 complex triggers JNK-mediated adipose tissue inflammation in obesity. Cell Metab. 2014;20(3):499-511.

Heymann JJ, Bulman WA, Maxfield RA, Powell CA, Halmos B, Sonett J, et al. Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. Cytojournal. 2014;11:12.

Wei Q, Zhang F, Richardson MM, Roy NH, Rodgers W, Liu Y, et al. CD82 restrains pathological angiogenesis by altering lipid raft clustering and CD44 trafficking in endothelial cells. Circulation. 2014;130(17):1493-504.

Laudano MA, E Osterberg C, Sheth S, Ramasamy R, Sterling J, Mukherjee S, et al. Microsurgical denervation of rat spermatic cord: safety and efficacy data. BJU Int. 2014;113(5):795-800.

Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, et al. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev. 2014;23(4):594-600.

Liao GJ, Gronowski AM, Zhao Z. Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation. Clin Chim Acta. 2014;428:44-50.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546-53.